scPharmaceuticals Past Earnings Performance
Past criteria checks 0/6
scPharmaceuticals's earnings have been declining at an average annual rate of -14.7%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been growing at an average rate of 94.4% per year.
Key information
-14.7%
Earnings growth rate
2.4%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 94.4% |
Return on equity | -655.6% |
Net Margin | -252.2% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?
Jun 27scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable
Jun 27The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 16Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?
Nov 25scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients
Oct 20FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure
Oct 10Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?
Jan 11Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?
Sep 02scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX
Aug 26Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like
Mar 09How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?
Nov 24Revenue & Expenses Breakdown
How scPharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 24 | -61 | 65 | 12 |
31 Mar 24 | 18 | -58 | 60 | 12 |
31 Dec 23 | 14 | -55 | 53 | 12 |
30 Sep 23 | 7 | -50 | 44 | 11 |
30 Jun 23 | 4 | -45 | 36 | 11 |
31 Mar 23 | 2 | -40 | 29 | 13 |
31 Dec 22 | 0 | -37 | 21 | 16 |
30 Sep 22 | 0 | -35 | 16 | 18 |
30 Jun 22 | 0 | -31 | 12 | 18 |
31 Mar 22 | 0 | -29 | 10 | 16 |
31 Dec 21 | 0 | -28 | 10 | 16 |
30 Sep 21 | 0 | -28 | 11 | 15 |
30 Jun 21 | 0 | -31 | 12 | 17 |
31 Mar 21 | 0 | -32 | 12 | 18 |
31 Dec 20 | 0 | -32 | 12 | 18 |
30 Sep 20 | 0 | -35 | 11 | 25 |
30 Jun 20 | 0 | -32 | 10 | 25 |
31 Mar 20 | 0 | -31 | 9 | 25 |
31 Dec 19 | 0 | -33 | 8 | 25 |
30 Sep 19 | 0 | -27 | 8 | 17 |
30 Jun 19 | 0 | -27 | 8 | 16 |
31 Mar 19 | 0 | -29 | 11 | 16 |
31 Dec 18 | 0 | -29 | 14 | 16 |
30 Sep 18 | 0 | -31 | 15 | 17 |
30 Jun 18 | 0 | -31 | 14 | 16 |
31 Mar 18 | 0 | -28 | 12 | 15 |
31 Dec 17 | 0 | -24 | 9 | 14 |
30 Sep 17 | 0 | -22 | 7 | 14 |
30 Jun 17 | 0 | -26 | 8 | 14 |
31 Mar 17 | 0 | -24 | 7 | 12 |
31 Dec 16 | 0 | -24 | 6 | 12 |
Quality Earnings: SCPH is currently unprofitable.
Growing Profit Margin: SCPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SCPH is unprofitable, and losses have increased over the past 5 years at a rate of 14.7% per year.
Accelerating Growth: Unable to compare SCPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).
Return on Equity
High ROE: SCPH has a negative Return on Equity (-655.61%), as it is currently unprofitable.